Crescent Biopharma, Inc. Q4 FY2023 earnings call

Harout Semerjian highlighted 2023 was a year of progress towards becoming a commercial company, with Q2 2024 expected to report top line results from the Phase III trial of uproleselan. Edwin Rock discussed the Phase III trial of uproleselan, including median follow-up over three years, clinical maturity, and trial hypotheses. Bruce Johnson talked about commercial readiness for uproleselan, potential market opportunity, and the completion of the Phase Ia trial for GMI-1687. Brian Hahn reviewed financials, noting cash and cash equivalents, and changes in research and development and general and administrative expenses.

No detailed product segment financial performance with absolute terms and revenue contribution % provided in the transcript.

Expect top line results from the Phase III trial of uproleselan in Q2 2024. Pending positive results from the Phase III trial, plan to submit a new drug application in the U.S. by the end of 2024. Completed the Phase Ia single ascending dose trial of subcutaneous GMI-1687.

Forward-looking statements involve assumptions, risks, and uncertainties. GlycoMimetics undertakes no obligation to update forward-looking statements. For risk factors affecting the company, refer to SEC filings.

Q: Whether the frontline results could be available in time to potentially be included together with the relapsed/refractory data and a filing, and how uproleselan would be used initially?

A: Harout Semerjian and Bruce Johnson responded, discussing regulatory pathways, initial use with patients fit for intensive therapy, and ongoing trials.

Q: Sense of event number in the Phase III study and timeline for reporting top line data, and details about the research collaboration with ASH RC?

A: Harout Semerjian and Edwin Rock responded, talking about event numbers, timeline for reporting, and the collaboration with ASH RC for GMI-1687 clinical development.

Q: Financial stipulations in the GMI-1687 collaboration and strategy for Europe regarding uproleselan?

A: Harout Semerjian responded, discussing financial component of the collaboration and ongoing plans for Europe regarding uproleselan